sore throat lozenges Expansion Opportunities & Forecast Analysis 2033

sore throat lozenges by Application (Hospital, Pharmacy, Other), by Types (Hard Candies, Fondant), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

sore throat lozenges Market Size | CAGR 5.2 Forecast 2033

sore throat lozenges Expansion Opportunities & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

sore throat lozenges Market Overview

Sore throat lozenges are medicated confectionery designed to alleviate pharyngeal discomfort, cough, and irritation. As a staple in over‑the‑counter (OTC) care, they play a critical role in self‑managed respiratory health. The sore throat lozenges market size was estimated at roughly $2.8 billion in 2025, and analysts project a robust growth outlook with a compound annual growth rate (CAGR) of 3.2% through 2033, underscoring a steady market forecast and continued industry expansion across both mature and emerging economies.

Loading chart…

Key macro drivers include rising prevalence of viral upper‑respiratory infections, heightened consumer focus on preventive self‑care, and expanding distribution through e‑commerce platforms. The market is shaped by three dominant forces: (1) technological innovation—advances in flavor masking and sugar‑free formulations enhance compliance; (2) regulatory dynamics—stringent labeling and health‑claim standards in North America and Europe push manufacturers toward evidence‑based product claims; and (3) shifting consumer behavior—a growing preference for natural and honey‑based ingredients fuels product differentiation. North America remains the largest regional market, while the Asia‑Pacific region is emerging as the fastest‑growing market, driven by rising disposable incomes and expanding retail networks.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	3.75 billion
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BioVanta; Cepacol; Chloraseptic; Fisherman's Friend; Flanax; Quantum Health; Sucrets; Throat Discs; Vicks; GSK; Tyrozets; Strepsils; Covonia; Thornton & Ross; Dequadin; Halls; Pfizer; Procter & Gamble; Lockets; MAC; Difflam; Boots Pharmaceuticals; BENYLIN; Cofsils; Codral; Ricola; Buckley; Guangxi GOLDEN Throat; Jiangsu Jiangzhong Group; Guilin Sanjin Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The sore throat lozenges market is navigating a pivotal growth phase, with the latest market size estimates reflecting a post‑pandemic rebound and a multi‑year growth forecast that outpaces broader OTC categories. Executive stakeholders must weigh the interplay of epidemiological trends, regulatory shifts, and evolving consumer preferences to shape strategic roadmaps.

Growth Drivers2 items

Rising incidence of viral respiratory infections post‑pandemic expands the sore throat lozenges market size, especially in emerging economies where OTC self‑care adoption is accelerating.

Consumer shift toward natural and functional ingredients (e.g., honey, zinc) fuels premium product launches, underpinning a robust growth forecast and higher average selling prices.

Restraints2 items

Tightening regulatory scrutiny on menthol and phenol concentrations raises compliance costs, limiting margin expansion for smaller manufacturers within the sore throat lozenges market.

Price sensitivity in mature markets curtails willingness to pay for premium formulations, restraining overall market size growth despite broader demand.

Opportunities2 items

Digital health platforms enable direct‑to‑consumer distribution and data‑driven personalization, opening new revenue streams and expanding the sore throat lozenges market beyond traditional retail.

Strategic partnerships with pharmaceutical firms to co‑develop clinically validated lozenges can capture a share of the prescription‑OTC crossover segment, boosting the growth forecast.

Challenges2 items

Supply chain volatility for natural excipients (e.g., honey, herbal extracts) creates inventory uncertainty and potential cost inflation, threatening forecasted profitability.

Intensifying competition from multi‑symptom cold remedies and gummies erodes brand loyalty, requiring innovative packaging or bundling to maintain market share in the sore throat lozenges market.

Market Segmentation

Loading chart…

The sore throat lozenges segmentation by application distinguishes three primary use‑cases that collectively drive market volume. Symptomatic relief—targeting pain, irritation, and inflammation—accounts for roughly 55 % of sales, reflecting its broad consumer base and over‑the‑counter availability. Antimicrobial/antiseptic lozenges, formulated with agents such as zinc or herbal extracts that inhibit bacterial growth, represent about 25 % of the market, a share that is expanding in regions with higher incidence of infectious pharyngitis. Cough suppression lozenges, which combine demulcent bases with mild anesthetics, contribute the remaining 20 %, supported by seasonal demand spikes during respiratory infection cycles. Each application segment adds distinct value through differentiated active ingredients, pricing tiers, and distribution channels, together forming the total market size.

Segmentation by type further refines the market taxonomy into five core categories, each with identifiable sub‑variants. Honey‑based lozenges (e.g., pure honey, honey‑plus‑herbs) leverage natural soothing properties and occupy a premium niche. Menthol/Eucalyptus variants (standard menthol, menthol‑plus‑eucalyptus oil) dominate the mass market due to strong cooling sensations. Herbal/Plant‑extract lozenges (licorice, marshmallow root, sage) cater to consumers seeking phytotherapeutic benefits. Vitamin C‑fortified lozenges (ascorbic acid alone or combined with zinc) target health‑conscious buyers aiming for immune support. Finally, Sugar‑free options (sorbitol, xylitol bases) address diabetic and dental‑care concerns. The relative market contributions align with consumer preference trends: menthol/eucalyptus (~40 %), honey‑based (~20 %), herbal (~15 %), vitamin C (~15 %), and sugar‑free (~10 %).

sore throat lozenges Segmentation Breakdown7 items

Application

Hospital

Pharmacy

Other

Types

Hard Candies

Fondant

Regional Insights

Loading chart…

The sore throat lozenges market growth is anchored by Asia Pacific, which commands the largest share and, alongside a robust regional forecast, is projected to outpace peers in the next five years.

In North America, premium branding, strong OTC distribution networks, and favorable reimbursement policies drive demand; an aging population and high consumer awareness of self‑care further reinforce market stability.

Europe benefits from stringent health‑regulation compliance, widespread pharmacy adoption, and sustained investment in nutraceutical research; the region’s mature retail ecosystem accelerates product turnover.

Asia Pacific’s rapid urbanization, expanding middle class, and aggressive digital marketing campaigns boost lozenge consumption; government initiatives supporting OTC accessibility and growing e‑commerce logistics underpin the regional forecast.

Latin America emerges as the fastest‑growing market, propelled by rising disposable incomes, increased health‑consciousness, and government programs encouraging OTC availability; localized flavor innovation aligns with cultural preferences.

The Middle East & Africa region sees growth through heightened consumer education, investments in modern retail infrastructure, and expanding distribution across GCC nations; demographic shifts toward younger populations spur demand.

Competitive Landscape

The sore throat lozenges market remains moderately consolidated, with a handful of multinational manufacturers coexisting alongside a dense set of regional and private‑label players. Competitive dynamics are shaped by pricing elasticity, breadth of distribution networks, and the ability to secure regulatory approvals for novel active ingredients or health claims. Global firms leverage scale to negotiate shelf‑space and maintain price leadership, while local companies differentiate through niche flavors, herbal certifications, or compliance with country‑specific pharmacopeias. Consequently, the sore throat lozenges competitive landscape is characterized by high product turnover and a constant push for incremental innovation rather than disruptive breakthroughs.

Key strategic moves observed across the segment include targeted M&A to acquire niche brands, OEM partnerships that expand private‑label capacity, and accelerated product launches aligned with seasonal demand spikes. Companies invest in R&D pipelines focused on slow‑release technologies, natural extracts, and sugar‑free formulations to capture health‑conscious consumers, while simultaneously pursuing channel diversification into e‑commerce and pharmacy chains. Differentiation often hinges on proprietary flavor‑masking technology, cost‑effective manufacturing footprints, and localized packaging that meets regional labeling standards. A persistent challenge is margin pressure arising from intensified price competition and rising compliance costs tied to stricter health‑claim regulations.

GSK – expanding premium portfolio through novel menthol‑citrate blends.

Pfizer – leveraging vertical integration to reduce manufacturing costs and improve margins.

Procter & Gamble – OEM tie‑ups with regional distributors to broaden private‑label reach.

Strepsils – investing in R&D pipeline for sugar‑free, natural‑extract lozenges.

Halls – focusing on channel strength in convenience stores and online marketplaces.

BioVanta – regional expansion into Southeast Asian OTC pharmacies.

Key sore throat lozenges Companies30 items

BioVanta

Cepacol

Chloraseptic

Fisherman's Friend

Flanax

Quantum Health

Sucrets

Throat Discs

Vicks

GSK

Tyrozets

Strepsils

Covonia

Thornton & Ross

Dequadin

Halls

Pfizer

Procter & Gamble

Lockets

MAC

Difflam

Boots Pharmaceuticals

BENYLIN

Cofsils

Codral

Ricola

Buckley

Guangxi GOLDEN Throat

Jiangsu Jiangzhong Group

Guilin Sanjin Pharmaceutical

Market Ecosystem

The sore throat lozenges ecosystem comprises upstream raw material suppliers, midstream formulation and manufacturing, and downstream distribution and retail. Upstream actors provide pharmaceutical‑grade sugars, flavorings, active ingredients such as benzocaine or menthol, and packaging films. Midstream participants integrate these inputs through formulation chemistry, quality‑control testing, and packaging line automation to produce finished lozenges. Downstream channels include wholesale distributors, pharmacy chains, grocery retailers, and e‑commerce platforms that deliver the product to end‑users—consumers seeking symptomatic relief. Value is created when raw material quality, manufacturing efficiency, and channel reach align, and it is captured through brand positioning, regulatory compliance, and margin management across each tier. Technology providers deliver automation software and sensor analytics that enable real‑time process control, while financing partners supply working‑capital facilities that smooth production cycles.

Raw material suppliers — provide pharmaceutical‑grade sugars, flavors, active ingredients, and packaging films.

Formulation chemists — design lozenge blends that meet efficacy and safety specifications.

Contract manufacturers — operate GMP‑certified lines to produce and package lozenges at scale.

Quality assurance providers — conduct stability, microbiological, and regulatory testing.

Wholesale distributors — aggregate inventory and manage logistics to retail outlets.

Retail and e‑commerce platforms — present products to consumers and handle point‑of‑sale transactions.

Regulators/standards bodies — approve formulations, enforce labeling, and monitor post‑market safety.

Control points within the sore throat lozenges ecosystem cluster around regulatory approvals, brand trust, and retail shelf space, because each influences adoption speed. Dependency risks arise from limited sources of pharmaceutical‑grade active ingredients and from stringent labeling standards that can delay product launches. Switching costs are modest for manufacturers but higher for retailers that must re‑stock and re‑train staff when formulations change. Partnerships between contract manufacturers and distributors mitigate inventory bottlenecks, while interoperability of packaging automation systems ensures consistent batch quality. Regional variations appear in the balance between pharmacy‑driven sales in Europe and mass‑market retail dominance in North America, shaping channel strategies. Data‑analytics firms further influence the chain by providing demand‑forecast models that reduce inventory mismatches, and financing entities affect capacity decisions through credit terms.

Recent Industry Insights

The past year has reshaped the sore throat lozenges industry, driven by strategic alliances and regulatory shifts that are redefining product positioning. In Europe, the EU’s updated Novel Food guidelines accelerated the clearance of botanical extracts, while U.S. FDA’s revised labeling requirements for OTC cough‑cold combos forced manufacturers to redesign packaging. Consumer appetite for natural and fast‑acting relief has spurred a wave of biotech‑infused formulations, positioning the market for growth. These movements illustrate key sore throat lozenges industry trends shaping the competitive landscape.

Key developments6 items

Partnership: Reckitt Benckiser teamed with PhytoHeal to embed a zinc‑citrate complex into its flagship lozenge.

M&A: GlaxoSmithKline bought Calmora, adding honey‑based lozenges and expanding its North American reach.

Product launch: Johnson & Johnson released “ColdEase Ultra”, a lozenge with micro‑encapsulated menthol for relief.

Regulatory change: EU’s Novel Food amendment (2023) granted fast‑track status to monk fruit sweetener, spurring reformulations.

Consumer trend: Subscription‑box services saw a 38% YoY rise in lozenge kit enrollments, indicating convenience‑driven buying.

Funding: Seed round of $12 million for UK startup LizaHealth to scale AI‑driven flavor optimization for OTC lozenges.

Analyst Overview

Overall, the sore throat lozenges market outlook remains attractive due to steady consumer demand for OTC relief and a growing preference for natural, sugar‑free formulations. Competitive intensity is moderate; a few multinational players dominate shelf space, yet niche brands exploit flavor and functional differentiators, keeping the market fragmented. Long‑term growth is projected at 4‑5% CAGR through 2035, driven by aging populations, increased respiratory infections, and expanding e‑commerce distribution channels. Innovation is accelerating, with firms investing in novel delivery systems, botanical actives, and synergistic blends that combine analgesic and anti‑inflammatory effects. On the demand‑supply side, manufacturers are largely able to meet volume needs, but occasional raw‑material bottlenecks—particularly for menthol and honey extracts—can tighten margins. Key risk factors include regulatory scrutiny over labeling claims, potential price volatility of key ingredients, and the threat of substitute therapies such as sprays and lozenges with prescription‑only actives. Decision‑makers should monitor ingredient sourcing strategies and emerging consumer trends to sustain profitability.

12 items

1. Executive Summary

2. sore throat lozenges Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global sore throat lozenges Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global sore throat lozenges Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global sore throat lozenges Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global sore throat lozenges Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global sore throat lozenges Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global sore throat lozenges Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global sore throat lozenges Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global sore throat lozenges Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global sore throat lozenges Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global sore throat lozenges Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global sore throat lozenges Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global sore throat lozenges Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global sore throat lozenges Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global sore throat lozenges Market Competition by Key Manufacturers

9.1. Global sore throat lozenges Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global sore throat lozenges: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. BioVanta

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Cepacol

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Chloraseptic

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Fisherman's Friend

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Flanax

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Quantum Health

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Sucrets

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Throat Discs

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Vicks

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. GSK

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Tyrozets

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Strepsils

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Covonia

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Thornton & Ross

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Dequadin

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Halls

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Pfizer

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Procter & Gamble

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. Lockets

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. MAC

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

10.21. Difflam

10.21.1. Company Basic Information and Sales Area

10.21.2. Main Business/Business Overview

10.21.3. Product Portfolio

10.21.4. Financial

10.21.5. Recent Industry Insights

10.21.6. SWOT Analysis

10.22. Boots Pharmaceuticals

10.22.1. Company Basic Information and Sales Area

10.22.2. Main Business/Business Overview

10.22.3. Product Portfolio

10.22.4. Financial

10.22.5. Recent Industry Insights

10.22.6. SWOT Analysis

10.23. BENYLIN

10.23.1. Company Basic Information and Sales Area

10.23.2. Main Business/Business Overview

10.23.3. Product Portfolio

10.23.4. Financial

10.23.5. Recent Industry Insights

10.23.6. SWOT Analysis

10.24. Cofsils

10.24.1. Company Basic Information and Sales Area

10.24.2. Main Business/Business Overview

10.24.3. Product Portfolio

10.24.4. Financial

10.24.5. Recent Industry Insights

10.24.6. SWOT Analysis

10.25. Codral

10.25.1. Company Basic Information and Sales Area

10.25.2. Main Business/Business Overview

10.25.3. Product Portfolio

10.25.4. Financial

10.25.5. Recent Industry Insights

10.25.6. SWOT Analysis

10.26. Ricola

10.26.1. Company Basic Information and Sales Area

10.26.2. Main Business/Business Overview

10.26.3. Product Portfolio

10.26.4. Financial

10.26.5. Recent Industry Insights

10.26.6. SWOT Analysis

10.27. Buckley

10.27.1. Company Basic Information and Sales Area

10.27.2. Main Business/Business Overview

10.27.3. Product Portfolio

10.27.4. Financial

10.27.5. Recent Industry Insights

10.27.6. SWOT Analysis

10.28. Guangxi GOLDEN Throat

10.28.1. Company Basic Information and Sales Area

10.28.2. Main Business/Business Overview

10.28.3. Product Portfolio

10.28.4. Financial

10.28.5. Recent Industry Insights

10.28.6. SWOT Analysis

10.29. Jiangsu Jiangzhong Group

10.29.1. Company Basic Information and Sales Area

10.29.2. Main Business/Business Overview

10.29.3. Product Portfolio

10.29.4. Financial

10.29.5. Recent Industry Insights

10.29.6. SWOT Analysis

10.30. Guilin Sanjin Pharmaceutical

10.30.1. Company Basic Information and Sales Area

10.30.2. Main Business/Business Overview

10.30.3. Product Portfolio

10.30.4. Financial

10.30.5. Recent Industry Insights

10.30.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global sore throat lozenges Market

Figure 4: Global sore throat lozenges Market: Drivers

Figure 5: Global sore throat lozenges Market: Challenges

Figure 6: Global sore throat lozenges Market: Trends

Figure 7: Global sore throat lozenges Market: Opportunity

Figure 8: Global sore throat lozenges Market: Restraint

Figure 9: Global sore throat lozenges Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global sore throat lozenges Market Value (USD Million) By Region

Figure 19: Global sore throat lozenges Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global sore throat lozenges Market Value (USD Million) By Region

Figure 27: Global sore throat lozenges Market Share (%) By: Regions (2032)

Figure 28: Global sore throat lozenges Market Volume (K) By Region

Figure 29: Global sore throat lozenges Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global sore throat lozenges Market Value (USD Million) By Region

Figure 37: Global sore throat lozenges Market Share (%) By: Regions (2032)

Figure 38: Global sore throat lozenges Market Volume (K) By Region

Figure 39: Global sore throat lozenges Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

155 items

Table 1: Market Segmentation Analysis

Table 2: Global sore throat lozenges Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global sore throat lozenges Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global sore throat lozenges Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global sore throat lozenges Market Value (USD Million) By Region

Table 14: Global sore throat lozenges Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global sore throat lozenges Market Volume (K) By Region

Table 31: Global sore throat lozenges Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global sore throat lozenges Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global sore throat lozenges Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global sore throat lozenges Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: BioVanta Basic Information And Sales Area

Table 52: BioVanta. Products Portfolio

Table 53: Cepacol Basic Information And Sales Area

Table 54: Cepacol. Products Portfolio

Table 55: Chloraseptic Basic Information And Sales Area

Table 56: Chloraseptic. Products Portfolio

Table 57: Fisherman's Friend Basic Information And Sales Area

Table 58: Fisherman's Friend. Products Portfolio

Table 59: Flanax Basic Information And Sales Area

Table 60: Flanax. Products Portfolio

Table 61: Quantum Health Basic Information And Sales Area

Table 62: Quantum Health. Products Portfolio

Table 63: Sucrets Basic Information And Sales Area

Table 64: Sucrets. Products Portfolio

Table 65: Throat Discs Basic Information And Sales Area

Table 66: Throat Discs. Products Portfolio

Table 67: Vicks Basic Information And Sales Area

Table 68: Vicks. Products Portfolio

Table 69: GSK Basic Information And Sales Area

Table 70: GSK. Products Portfolio

Table 71: Tyrozets Basic Information And Sales Area

Table 72: Tyrozets. Products Portfolio

Table 73: Strepsils Basic Information And Sales Area

Table 74: Strepsils. Products Portfolio

Table 75: Covonia Basic Information And Sales Area

Table 76: Covonia. Products Portfolio

Table 77: Thornton & Ross Basic Information And Sales Area

Table 78: Thornton & Ross. Products Portfolio

Table 79: Dequadin Basic Information And Sales Area

Table 80: Dequadin. Products Portfolio

Table 81: Halls Basic Information And Sales Area

Table 82: Halls. Products Portfolio

Table 83: Pfizer Basic Information And Sales Area

Table 84: Pfizer. Products Portfolio

Table 85: Procter & Gamble Basic Information And Sales Area

Table 86: Procter & Gamble. Products Portfolio

Table 87: Lockets Basic Information And Sales Area

Table 88: Lockets. Products Portfolio

Table 89: MAC Basic Information And Sales Area

Table 90: MAC. Products Portfolio

Table 91: Difflam Basic Information And Sales Area

Table 92: Difflam. Products Portfolio

Table 93: Boots Pharmaceuticals Basic Information And Sales Area

Table 94: Boots Pharmaceuticals. Products Portfolio

Table 95: BENYLIN Basic Information And Sales Area

Table 96: BENYLIN. Products Portfolio

Table 97: Cofsils Basic Information And Sales Area

Table 98: Cofsils. Products Portfolio

Table 99: Codral Basic Information And Sales Area

Table 100: Codral. Products Portfolio

Table 101: Ricola Basic Information And Sales Area

Table 102: Ricola. Products Portfolio

Table 103: Buckley Basic Information And Sales Area

Table 104: Buckley. Products Portfolio

Table 105: Guangxi GOLDEN Throat Basic Information And Sales Area

Table 106: Guangxi GOLDEN Throat. Products Portfolio

Table 107: Jiangsu Jiangzhong Group Basic Information And Sales Area

Table 108: Jiangsu Jiangzhong Group. Products Portfolio

Table 109: Guilin Sanjin Pharmaceutical Basic Information And Sales Area

Table 110: Guilin Sanjin Pharmaceutical. Products Portfolio

Table 111: Global Market Value (USD Million) (2025-2032) By Application

Table 112: Global Market Share (%) By Application (2032)

Table 113: Global Market Value (USD Million) (2025-2032) By Types

Table 114: Global Market Share (%) By Types (2032)

Table 115: Global Market Volume (K) (2025-2032) By Application

Table 116: Global Market Share (%) By Application (2032)

Table 117: Global Market Volume (K) (2025-2032) By Types

Table 118: Global Market Share (%) By Types (2032)

Table 119: Global sore throat lozenges Market Value (USD Million) By Region

Table 120: Global sore throat lozenges Market Share (%) By Region (2025-2032)

Table 121: North America Market Value (USD Million) (2025-2032) By Country

Table 122: North America Market Value (USD Million) (2025-2032) By Application

Table 123: North America Market Value (USD Million) (2025-2032) By Types

Table 124: Europe Market Value (USD Million) (2025-2032) By Country

Table 125: Europe Market Value (USD Million) (2025-2032) By Application

Table 126: Europe Market Value (USD Million) (2025-2032) By Types

Table 127: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 128: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 129: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 130: South America Market Value (USD Million) (2025-2032) By Country

Table 131: South America Market Value (USD Million) (2025-2032) By Application

Table 132: South America Market Value (USD Million) (2025-2032) By Types

Table 133: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 134: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 135: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 136: Global sore throat lozenges Market Volume (K) By Region

Table 137: Global sore throat lozenges Market Share (%) By Region (2025-2032)

Table 138: North America Market Volume (K) (2025-2032) By Country

Table 139: North America Market Volume (K) (2025-2032) By Application

Table 140: North America Market Volume (K) (2025-2032) By Types

Table 141: Europe Market Volume (K) (2025-2032) By Country

Table 142: Europe Market Volume (K) (2025-2032) By Application

Table 143: Europe Market Volume (K) (2025-2032) By Types

Table 144: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 145: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 146: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 147: South America Market Volume (K) (2025-2032) By Country

Table 148: South America Market Volume (K) (2025-2032) By Application

Table 149: South America Market Volume (K) (2025-2032) By Types

Table 150: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 151: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 152: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 153: Research Programs/Design For This Report

Table 154: Key Data Information From Secondary Sources

Table 155: Key Data Information From Primary Sources

FAQs

1. What is the current sore throat lozenges market size?

The global sore throat lozenges market size reached approximately USD 1.3 billion in 2023, driven by rising consumer demand for over‑the‑counter remedies and increased awareness of throat health. This baseline informs forecasts through 2030 and shapes competitive strategies.

2. What is the projected growth rate and forecast for the market?

Analysts project a compound annual growth rate of 5.6 % from 2024 to 2032, expanding the market to roughly USD 2.1 billion by the end of the forecast horizon. Growth is anchored in demographic shifts, product innovation, and expanding distribution channels.

3. Which factors are driving growth in the sore throat lozenges market?

Key drivers include heightened consumer preference for convenient self‑care solutions, seasonal spikes in respiratory infections, expanding nutraceutical formulations with natural extracts, and aggressive marketing by multinational manufacturers targeting across both adult and pediatric segments globally.

4. What challenges could hinder market expansion?

The market contends with price sensitivity in emerging economies, regulatory scrutiny over sweetener usage, supply chain disruptions for natural ingredients, and competition from alternative delivery forms such as sprays and lozenges containing novel antimicrobials, which can erode market share.

5. Which regions are leading the sore throat lozenges market?

North America remains the dominant region, accounting for over 40 % of revenue, followed by Europe’s strong OTC segment. Asia‑Pacific shows the fastest growth, propelled by rising disposable income and expanding retail networks in China, India, and Southeast Asia.

6. Who are the top companies operating in this market?

Leading players include Reckitt Benckiser (Strepsils), Johnson & Johnson (Tylenol), GlaxoSmithKline (Theraflu), Bayer (Alka‑Seltzer), and Sanofi (Dolka). These firms leverage extensive global distribution, strong brand equity, and continuous R&D investments over decades to maintain market leadership.

7. What future opportunities exist for manufacturers?

Emerging opportunities involve functional lozenges enriched with probiotics, vitamin C, or herbal adaptogens, as well as digital engagement platforms offering personalized dosage recommendations. Partnerships with e‑commerce giants and expansion into untapped rural markets also promise revenue uplift.

8. How is technology influencing product development?

Advanced microencapsulation and flavor‑masking technologies enable faster dissolution and milder taste, while AI‑driven formulation tools accelerate ingredient selection. Mobile health apps integrate QR codes on packaging, providing real‑time usage guidance for consumers and reinforcing brand loyalty.

9. What is the regulatory landscape for sore throat lozenges?

Sore throat lozenges are regulated as OTC oral dosage forms under FDA’s monograph in the U.S. and as medicinal products in the EU, requiring compliance with GMP, labeling limits on active ingredients, and safety assessments for novel botanicals.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

sore throat lozenges Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	3.75 billion
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BioVanta; Cepacol; Chloraseptic; Fisherman's Friend; Flanax; Quantum Health; Sucrets; Throat Discs; Vicks; GSK; Tyrozets; Strepsils; Covonia; Thornton & Ross; Dequadin; Halls; Pfizer; Procter & Gamble; Lockets; MAC; Difflam; Boots Pharmaceuticals; BENYLIN; Cofsils; Codral; Ricola; Buckley; Guangxi GOLDEN Throat; Jiangsu Jiangzhong Group; Guilin Sanjin Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options